Does Medicaid Cover GLP-1 Drugs (Ozempic, Wegovy, Mounjaro) by State? (2026)

Direct Answer: Which GLP-1 Indications Medicaid Must Cover

Federal Medicaid law requires all 50 states to cover GLP-1 medications when prescribed for type 2 diabetes, established cardiovascular disease with overweight or obesity (FDA-approved March 2024), obstructive sleep apnea with obesity (FDA-approved December 2024), and nonalcoholic steatohepatitis (MASH). These are mandatory because they are not excluded drug classes under the Medicaid Drug Rebate Program. States cannot opt out of covering them on formulary for eligible patients.

Obesity as a standalone indication is a different legal category. Federal law (Social Security Act Section 1927(d)(2)) allows states to exclude drugs used only for weight reduction from Medicaid coverage. Most states exercise this exclusion. As of January 2026, only 13 states have elected to cover GLP-1s for chronic weight management, and that number dropped from 16 in 2025 after four states ended obesity-only coverage citing budget constraints of roughly $1,000 per prescription per month in gross spending. See KFF's Medicaid GLP-1 coverage tracker for the most current state policy updates.

State-by-State GLP-1 Obesity Coverage Table (2026)

The following 13 states cover at least one GLP-1 drug for chronic weight management under Medicaid fee-for-service in 2026, subject to prior authorization in every case. All remaining states cover GLP-1s only for mandatory indications (type 2 diabetes, CVD, sleep apnea).

States That Dropped GLP-1 Obesity Coverage in 2026

Four states ended GLP-1 obesity coverage effective January 1, 2026, citing unsustainable spending growth. Medicaid gross spending on GLP-1 drugs nationally reached nearly $9 billion in 2024, up from $1 billion in 2019, and the cost per prescription exceeded $1,000 in 2024 at gross prices. The four states that dropped coverage:

• California (Medi-Cal): dropped obesity-only GLP-1 coverage effective January 1, 2026. Coverage for type 2 diabetes and cardiovascular indications remains in place under Medi-Cal.
• New Hampshire Medicaid: dropped obesity-only GLP-1 coverage effective January 1, 2026.
• Pennsylvania Medicaid: dropped adult obesity GLP-1 coverage for members 21 and older effective January 1, 2026.
• South Carolina Medicaid: dropped obesity-only GLP-1 coverage effective January 1, 2026.
• North Carolina Medicaid: temporarily dropped coverage in October 2025 due to a budget impasse, then reinstated it in December 2025. Coverage is currently active.

What the CMS BALANCE Model Means for Medicaid GLP-1 Access

CMS launched the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) in December 2025 as a voluntary five-year program running from May 1, 2026 through December 31, 2031. State Medicaid programs can apply to join through January 1, 2027. Under the model, CMS has negotiated lower net prices with manufacturers for seven GLP-1 drugs: all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the KwikPen version of Zepbound. States that join the BALANCE Model agree to provide these drugs to qualifying beneficiaries at the negotiated price in exchange for coverage of chronic weight management, even if the state previously did not cover obesity GLP-1s.

The BALANCE Model is significant because it could expand GLP-1 obesity coverage to states that previously found the cost prohibitive. The net price for state Medicaid programs under BALANCE is confidential, but the Medicare side of the model prices drugs at $245 per month, a substantial reduction from list prices above $1,000 per month. Beneficiaries in participating states who qualify clinically (BMI thresholds plus comorbidity criteria specified in the BALANCE agreement) would access these drugs at standard Medicaid cost-sharing, which for most low-income enrollees is zero or minimal.

Prior Authorization Requirements: What Medicaid Typically Requires

Every state Medicaid program that covers GLP-1 drugs for any indication requires prior authorization. The specific criteria differ by state and by the drug's indication, but a common framework applies across most covering states in 2026.

• Type 2 diabetes prior auth: prescriber must document an HbA1c above individualized goal despite adequate use of first-line agents (usually metformin or an SGLT-2 inhibitor). Preferred GLP-1 drugs vary by state formulary.
• Cardiovascular risk reduction prior auth: must document established cardiovascular disease (prior myocardial infarction, stroke, or symptomatic peripheral artery disease) plus BMI of 27 or higher. Wegovy is the primary drug for this indication in most Medicaid formularies.
• Obesity-only prior auth (13-state coverage): BMI of 30 or higher, or BMI of 27 or higher with at least one comorbidity (hypertension, type 2 diabetes, hyperlipidemia, or obstructive sleep apnea). Most states also require documentation of prior 6-month diet and exercise counseling attempt.
• Continuing authorization: most states require re-authorization every 6 to 12 months and may require documented weight loss of 5% or more in the prior authorization period to continue coverage.
• Prescriber type: most states accept prescriptions from primary care physicians, internists, and endocrinologists. Some states require specialist (endocrinologist or obesity medicine specialist) attestation for obesity-only prior authorization.

Alternatives If Your State Medicaid Does Not Cover GLP-1 for Weight Loss

For Medicaid enrollees in the 37 states that do not cover GLP-1s for obesity, several pathways may still provide access or meaningful price reduction in 2026.

• Check whether you have a qualifying comorbidity. If you have established cardiovascular disease (prior heart attack, stroke, or PAD) plus a BMI of 27 or higher, Wegovy is now mandatory in all 50 states under the cardiovascular risk reduction indication. This is the most common coverage path for people who have obesity but live in non-covering states.
• Check for obstructive sleep apnea. Medicaid covers Wegovy for OSA with BMI 30 or higher in all 50 states as of December 2024. An OSA diagnosis from a sleep study plus the appropriate BMI qualifies you for mandatory coverage regardless of your state's obesity-only policy.
• Manufacturer patient assistance programs. Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) both operate patient assistance programs for uninsured or underinsured patients. Income thresholds vary. Apply at novonordiskpatientsupport.com and lilly.com/patient-assistance.
• Federally Qualified Health Centers (FQHCs). FQHCs operate on a sliding-fee scale and can prescribe GLP-1 drugs for eligible patients. Some FQHCs access 340B pricing on GLP-1 drugs, which can substantially reduce out-of-pocket cost compared to retail pharmacy prices. Find an FQHC at findahealthcenter.hrsa.gov.
• BALANCE Model expansion. If your state applies to join the CMS BALANCE Model (applications accepted through January 2027), GLP-1 obesity coverage may become available even if your state currently excludes it. Monitor your state Medicaid agency website for BALANCE enrollment announcements.

How to Apply for Medicaid GLP-1 Coverage

If you are already enrolled in Medicaid and your prescriber believes a GLP-1 is medically appropriate, the steps below apply across all states that cover GLP-1 drugs for any indication.

• Step 1: Confirm your Medicaid managed care plan's drug formulary. Call the pharmacy benefit number on your Medicaid card or log into your plan's member portal. Ask specifically whether the GLP-1 your prescriber recommends is on formulary and under which indication.
• Step 2: Have your prescriber document the medical justification. For diabetes, this means recent HbA1c lab values and current medication list. For CVD, this means the ICD-10 code for the qualifying cardiovascular event plus your height and weight. For obesity-only states, this means documented BMI measurement and records of a prior 6-month diet and exercise program.
• Step 3: Submit the prior authorization request. Your prescriber's office typically submits this directly to your Medicaid plan. The electronic PA process takes 3 to 5 business days for non-urgent requests. Urgent requests (clinically critical need) must be decided within 3 business days or 72 hours.
• Step 4: If denied, appeal within 60 days. Denials must be in writing with a specific clinical reason. You can request an expedited appeal if your health would be seriously harmed by the delay. The internal appeal must be decided within 30 days (non-urgent) or 3 days (urgent). If the internal appeal fails, request a state fair hearing through your state Medicaid office.
• Step 5: After approval, fill the prescription at a pharmacy in your Medicaid plan's network. Most Medicaid plans cover GLP-1 injections at retail pharmacies with standard Medicaid cost-sharing, which for most low-income enrollees is zero or a nominal copay under $4.

Does Medicaid cover Ozempic for type 2 diabetes?

Yes. All 50 state Medicaid programs must cover semaglutide (Ozempic) for type 2 diabetes because it is an FDA-approved drug for a non-excluded indication under federal law. Prior authorization applies in most states and typically requires documentation that first-line agents (metformin, SGLT-2 inhibitors) have not achieved adequate blood sugar control. Formulary placement varies, so call your Medicaid plan to confirm Ozempic is on the preferred list or whether a step through a comparable GLP-1 is required first.

Does Medicaid cover Wegovy for weight loss?

Only in 13 states as of January 2026: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin. All remaining states exclude Wegovy for obesity-only use. Wegovy is covered in all 50 states when prescribed for cardiovascular risk reduction in patients with established CVD and BMI 27 or higher, or for obstructive sleep apnea with BMI 30 or higher, because those are mandatory indications under federal Medicaid law.

Does Medicaid cover Mounjaro (tirzepatide) or Zepbound?

Mounjaro (tirzepatide) for type 2 diabetes is covered in all 50 states as a mandatory FDA-approved indication. Zepbound (tirzepatide for weight management) is covered for obesity only in states that have active obesity GLP-1 coverage, which as of January 2026 is 13 states. Zepbound in KwikPen form is also included in the BALANCE Model drug list for states that join. As with all Medicaid GLP-1 coverage, prior authorization is required.

Why did California (Medi-Cal) stop covering GLP-1 for weight loss?

Medi-Cal ended obesity-only GLP-1 coverage effective January 1, 2026, citing state budget pressure. The cost per GLP-1 prescription reached approximately $1,000 per month at gross prices, and the volume of prescriptions grew sharply. Medi-Cal still covers GLP-1 drugs in full for type 2 diabetes, cardiovascular risk reduction, and obstructive sleep apnea because those are federally mandated indications that California cannot exclude.

What is the BMI requirement for Medicaid GLP-1 coverage?

For obesity-only coverage in the 13 covering states, the typical requirement is BMI 30 or higher, or BMI 27 or higher with at least one qualifying comorbidity such as hypertension, type 2 diabetes, hyperlipidemia, or obstructive sleep apnea. Michigan tightened its threshold to BMI 40 or higher (morbid obesity) effective January 2026. For the cardiovascular risk reduction indication (all 50 states), the threshold is BMI 27 or higher plus documented established cardiovascular disease.

What is the BALANCE Model and does it apply to Medicaid?

The BALANCE Model is a voluntary CMS program launched December 2025 that runs from May 1, 2026 through December 31, 2031. State Medicaid programs can apply to join through January 1, 2027. Participating states receive negotiated lower net prices from manufacturers for seven GLP-1 drugs (including Wegovy, Ozempic, Mounjaro, Zepbound KwikPen) in exchange for agreeing to cover them for chronic weight management. The model could expand obesity GLP-1 access beyond the current 13 states. The Medicare side of BALANCE prices drugs at $245 per month; the Medicaid net price is confidential.

Can I get GLP-1 drugs through Medicaid if I am denied for weight loss?

Potentially, through two federal fallback paths. First, if you have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) plus BMI 27 or higher, Wegovy is mandatory in all 50 states under the cardiovascular risk reduction indication. Second, if you have confirmed obstructive sleep apnea plus BMI 30 or higher, Wegovy is mandatory for that indication in all 50 states. If neither applies, alternatives include manufacturer patient assistance programs (Novo Nordisk, Eli Lilly), Federally Qualified Health Centers with 340B pricing, and monitoring your state for BALANCE Model participation.

How long does Medicaid GLP-1 prior authorization take?

Standard prior authorization decisions are required within 3 to 5 business days under federal Medicaid managed care rules. Urgent prior authorization (when a 5-day wait would seriously harm your health) must be decided within 72 hours. Your prescriber's office submits the PA request electronically. If you receive a denial, you have 60 days to appeal internally, and you can simultaneously request continuation of the drug during the appeal period while the dispute is resolved.